TABLETING 67
DIGITAL DESIGN SCHEMEannounced I
£20.4 million project set to transform UK pharmaceutical development and manufacturing
n the UK, a newly launched major collaborative project is set to transform the pharmaceutical industry by enabling the manufacturing processes of the innovative medicines of the future to be designed digitally. Te ADDoPT (Advanced
Digital Design of Pharmaceutical Terapeutics) project addresses a key challenge for the pharmaceutical industry; getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure access for patients. Te collaboration will pursue this goal by developing and implementing advanced digital design techniques that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes. ‘Digital design’ combines
research insight and mechanistic modelling to provide links
between raw materials, formulation, manufacturing processes and drug product quality. It spans all operations, processes and procedures during the development and manufacture of medicines, and their in vivo application. Alison Clough, acting chief
executive of the Association of the British Pharmaceutical Industry, comments: “We welcome the Government’s commitment to continuing to develop the UK’s life sciences sector. Tis project will help to put the UK in a position to make innovative medicines available to UK patients more quickly by future-proofing our advanced pharmaceutical manufacturing sector. By reducing the risks associated with the manufacture of medicines we can provide the UK with a competitive advantage in a globally significant sector.” ADDoPT is a four-
year collaboration between government, industry and
academia. Led by Process Systems Enterprise and supported by the Medicines Manufacturing Industry Partnership (MMIP), it involves pharmaceutical companies Pfizer, GlaxoSmithKline, AstraZeneca and Bristol-Myers Squibb, as well as leading UK universities, research centres and knowledge-driven technology SMEs.
MMIP is a partnership set up jointly by ABPI and the BioIndustry Association (BIA). BIA chief executive, Steve Bates, says: “Tis is a great result for UK medicines manufacturing and I look forward to seeing the new technology being applied to biologics so that we can continue to address unmet patient need with the most innovatively designed and effective treatments possible.” ADDoPT builds on
UK excellence in big data, mechanistic modelling, process optimisation and control to
establish a highly competitive UK knowledge value supply chain for the pharmaceutical sector that will seek to: protect UK drug manufacturing and support future growth; encourage reshoring of existing pharmaceutical production; contribute to job creation and safeguarding in the pharmaceutical supply chain; enhance UK skills and capabilities through the training of operators and scientists in new design and control tools and methodologies; and get new innovative medicines to market as efficiently as possible to ensure access for patients. Project lead Sean
Bermingham of Process Systems Enterprise states: “By building on UK excellence in process modelling, optimisation and control, we can give UK pharmaceutical development and manufacturing a genuine competitive advantage in this sector.”
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84